A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.
Nora SundahlKatrien De WolfSylvie RotteyKarel DecaesteckerDaan De MaeseneerAnnabel MeiresonEls GoetghebeurValérie FonteyneSofie VerbekePieter De VisschereDries ReyndersMireille Van GeleLieve BrochezPiet OstPublished in: Journal of translational medicine (2017)
The progress made in the field of immunotherapy has lead to promising breakthroughs in various solid malignancies. Unfortunately, the majority of patients do not respond. The current trial will shed light on the toxicity and potential anti-tumor activity of the combination of radiotherapy with anti-PD1 treatment and may identify potential new markers for response and resistance to therapy. Trial registration this trial is registered on clinicaltrials.gov (NCT02826564).
Keyphrases
- phase iii
- study protocol
- phase ii
- clinical trial
- early stage
- locally advanced
- squamous cell carcinoma
- end stage renal disease
- newly diagnosed
- small cell lung cancer
- open label
- randomized controlled trial
- oxidative stress
- ejection fraction
- stem cells
- prognostic factors
- bone marrow
- risk assessment
- advanced non small cell lung cancer
- tyrosine kinase